ClinicalTrials.gg
CompletedNCT03691090Updated Dec 7, 2022

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

A Phase 3 interventional study of SHR-1210 and Placebo in Advanced Esophageal Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-07.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
596
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing camrelizumab in Esophageal Neoplasms — 5 open to participants now, 6 under way, none of them phase 3. camrelizumab · Esophageal Neoplasms.

Enrollment
Largest of 17
596 · median 63
Started
2018
with 1 other
Phase 3
3 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
3 of 17
Jiangsu HengRui Medicine Co., Ltd.

Among the 17 studies testing camrelizumab in Esophageal Neoplasms, this one has the largest enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 5th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

5 of the 17 studies testing camrelizumab in Esophageal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing camrelizumab in Esophageal Neoplasms, or all of them as a file.
02

Study summary

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel +cisplatin as 1L therapy for advanced esophageal cancer patients in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Read the detailed description

In this study, eligible subjects will be randomized into study arm or control arm. Treatment cycles of chemotherapy will be at most 6 cycles which would be decided by the investigators. Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) and overall survival (OS) will be the primary outcomes.

03

Conditions studied

  • Advanced Esophageal Cancer

Keywords

  • PD-1Antibody
  • advanced esophageal cancer
  • paclitaxel
  • cisplatin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed unresectable local advanced/recurrent or esophageal squamous cell carcinoma;
  2. No previous systemic anti-tumor treatment;
  3. Subjects must have at least one measurable tumor lesion per 1.1;
  4. Tissue samples should be provided for biomarkers (such as ) analysis;
  5. : 0-1;
  6. Adequate organ and bone marrow function;

Exclusion criteria

Exclusion Criteria:

  1. Allergic to monoclonal antibodies, any SHR-1210 components, paclitaxel, cisplatin and other platinum drugs;
  2. Prior therapy as follow:

    1. Anti- or anti-PD-L1;
    2. Any experimental drugs within 4 weeks of the first dose of study medication;
    3. Received major operations or serious injuries within 4 weeks of the first dose of study medication;
    4. Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication;
  3. Not recovered to ≤ 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment;
  4. Subjects with any active disease or history of autoimmune disease;
  5. Pregnancy or breast feeding;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
596 participants (actual)

Study arms

  • Experimental
    SHR-1210 + paclitaxel + cisplatin

    Paclitaxel 175mg/m2, Day 1,cisplatin 75mg/m2,Day 1,SHR-1210 200mg,Day 2,every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance

    Drug: SHR-1210 · Drug: paclitaxel · Drug: cisplatin

  • Active comparator
    placebo+paclitaxel + cisplatin

    Paclitaxel 175mg/m2, Day 1,cisplatin 75mg/m2,Day 1,placebo,Day 2,every 3 weeks, maximum 6 cycles, then placebo maintenance

    Drug: Placebo · Drug: paclitaxel · Drug: cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. PFS assessed by IRC

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

  2. OS

    OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier.

    Time frame: approximately 22 months

Secondary outcomes

  1. PFS assessed by investigators

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

  2. 6 and 9 month OS rate

    OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier.

    Time frame: approximately 6 and 9 months

  3. ORR

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

  4. DCR

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

  5. DoR

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

  6. AE

    adverse events

    Time frame: approximately 22 months

Other outcomes

  1. Antidrug Antibodies (ADAs)

    To evaluate the incidence of ADAs against SHR-1210

    Time frame: approximately 22 months

07

Study locations

1 site
  • Cancer Center of Sun-Yat Sen University (CCSYSU)
    Guangzhou, Guangdong 510060, China
08

References and documents

Publications

  • Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. PubMed 34519801 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Oct 2020, 22 months.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2018
First posted
Oct 1, 2018
StartActual
Dec 3, 2018
Primary completionActual
Oct 30, 2020
CompletionActual
Apr 30, 2022
Last update
Dec 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03691090
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Dec 3, 2018
Primary completion
Oct 30, 2020
Completion
Apr 30, 2022
Last update
Dec 7, 2022

Study contacts

Ruihua Xu
principal investigator · Cancer Center of Sun-Yat Sen University (CCSYSU)
Qing Yang
study director · Jiangsu HengRui Medicine Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion